Half-year report · HY
3151.TEDINET S100X430
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥300.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥600.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥297.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥2.9bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥5.0bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥7.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.6bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥7.5bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.7bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.0bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥5.0bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥2.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥313.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥299.4bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥317.6bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥203.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥192.1bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥109.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥107.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥109.6bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥23.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥20.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥16.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥31.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥8.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥9.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥102.84 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.02 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.75 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 34.5% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 47
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥6.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥6.9bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | ¥31m |
| Medical Products Wholesalereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥287.4bn |
| Medical Products Wholesalereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥282.0bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥5.5bn |
| Medical Products Wholesalereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2.1bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.6bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.2bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.4bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥122m |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥592m |
| Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥9.9bn |
| Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥9.9bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6m |
| Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥135m |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥108m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥307.1bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥300.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.9bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥6.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥6.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥0 |
| Medical Products Wholesalereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥285.0bn |
| Medical Products Wholesalereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥279.5bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Medical Products Wholesalereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.7bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| Nursing Care Related Rental And Other Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| Nursing Care Related Rental And Other Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥88m |
| Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥9.7bn |
| Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥9.7bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6m |
| Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥96m |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥144m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥303.9bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥297.1bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.8bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 539
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1InterimInstant | 16084000000 | JPY |
| Cash and cash equivalents | InterimInstant | 20200000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 33247000000 | JPY |
| Merchandise and finished goods | InterimInstant | 33476000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 5000000 | JPY |
| Raw materials and supplies | InterimInstant | 6000000 | JPY |
| Payrolls compensation and allowances sga | Prior1InterimDuration | 8882000000 | JPY |
| Payrolls compensation and allowances sga | InterimDuration | 9005000000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 1437000000 | JPY |
| Provision for bonuses sga | InterimDuration | 1454000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 16000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 221000000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1InterimDuration | 78000000 | JPY |
| Provision of allowance for doubtful accounts sga | InterimDuration | -63000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 279541000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E22440-000PharmacyBusinessReportableSegmentMember | 9725000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 5647000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E22440-000PharmaceuticalBusinessReportableSegmentMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E22440-000NursingCareRelatedRentalAndOtherBusinessReportableSegmentMember | 2165000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 297079000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 5454000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E22440-000PharmacyBusinessReportableSegmentMember | 6000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 0 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E22440-000PharmaceuticalBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E22440-000NursingCareRelatedRentalAndOtherBusinessReportableSegmentMember | 1341000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 6802000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 284995000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E22440-000PharmacyBusinessReportableSegmentMember | 9731000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 5647000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E22440-000PharmaceuticalBusinessReportableSegmentMember | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E22440-000NursingCareRelatedRentalAndOtherBusinessReportableSegmentMember | 3507000000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 303881000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 2724000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E22440-000PharmacyBusinessReportableSegmentMember | 96000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 144000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E22440-000PharmaceuticalBusinessReportableSegmentMember | － | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E22440-000NursingCareRelatedRentalAndOtherBusinessReportableSegmentMember | -88000000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 2876000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 297079000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -6802000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -6802000000 | JPY |
| Net sales | Prior1InterimDuration | 297079000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -0 | JPY |
| Operating income | Prior1InterimDuration | 2876000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 281967000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E22440-000PharmacyBusinessReportableSegmentMember | 9870000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 6178000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E22440-000PharmaceuticalBusinessReportableSegmentMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |